Pembrolizumab versus Ipilimumab in Advanced Melanoma
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
Explore 302 academic publications
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...
ADVERTISEMENT RETURN TO ISSUEPREVReviewNEXTCellulose Nanocrystals: Chemistry, Self-Assembly, and ApplicationsYoussef Habibi†, Lucian A. Lucia*†, and Orlando J. Rojas†‡View Autho...
Description of System: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance program that provides estimates of the prevalence of ASD amo...
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who h...
We combined targeted chemistry and computational design to create a crystal structure for porous chromium terephthalate, MIL-101, withverylargeporesizes and surface area. Its ze...
One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov...
Abstract. The First Key Symposium was held in Stockholm, Sweden, 2–5 September 2003. The aim of the symposium was to integrate clinical and epidemiological perspectives on the t...
A historical perspective on the application of molecular dynamics (MD) to biological macromolecules is presented. Recent developments combining state-of-the-art force fields wit...
Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously un...